In last trading session, the stock price of Reve Technologies Inc (OTCMKTS:BSSP) gained 100% to close the day at $0.00040. The gains came at a massive share volume of 554.95 million compared to average share volume of 164.25 million.

The buzz

Reve a development stage technology firm reported that it has effectively completed its Purchase and Sale Agreement with Canteck Pharma, Inc., and certain majority shareholders of the company. Canteck has advanced and has patented technology, termed as “Irreversible Pepsin Fraction.” The parties will persist to meet post-closing requirements. Reve stated that the Irreversible Pepsin Fraction is a therapeutic technology to support a wide range of applications. It do not have any neurological, hematological and gastrointestinal side effects.

The highlights

As previously stated the Purchase Agreement puts in action the plan through which Reve acquires 100% ownership interest in Canteck for its planned and current operations and the Sub Licensing deal for Irreversible Pepsin Fraction particular to the Cancer indication, for Mexico. In latest developments, Reve reported that it has acquired its import export license for IPF with Mexico and has been educated by third parties related to the permitting procedures with hospitals in Mexico that the company can anticipate its initial permitting become effective by May 2016 for the firm to commence sales.

The management speaks

Dennis Alexander, the CEO of Reve, said that they are delighted with the closing procedures with Canteck for immunotherapeutic technology for specific designated Cancer indications. Further, they look forward to address the management cultures and synergies, changing and adopting the company’s name to “Cantech Holding, Inc.”, thus progressing on the platform that Reve colleagues at Canteck and Reve itself have reported in building a portfolio of advanced oncology technologies. Harry Zhabilov, the Chief Scientist of the firm said that they intend to work together for getting permit approvals for IPF technology.